4'-trifluoromethyl-biphenyl-2-ylmethyl bromide | 167021-50-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-trifluoromethyl-biphenyl-2-ylmethyl bromide
• 英文别名: 2-bromomethyl-4'-trifluoromethylbiphenyl；2-[4-(trifluoromethyl)phenyl]benzyl bromide；2-bromomethyl-4'-trifluoromethyl-biphenyl；1-(bromomethyl)-2-[4-(trifluoromethyl)phenyl]benzene
• CAS: 167021-50-3
• 化学式: C₁₄H₁₀BrF₃
• 分子量: 315.133
• InChiKey: FJRRLFDAMZYROV-UHFFFAOYSA-N

物化性质

• 沸点：
  339.3±42.0 °C(Predicted)
• 密度：
  1.447±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-cyclohexylmethyl-3-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]benzamide 、 4'-trifluoromethyl-biphenyl-2-ylmethyl bromide 在 sodium hydroxide 、 四丁基硫酸氢铵 、 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 5.5h， 以34%的产率得到N-cyclohexylmethyl-3-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-N-[(4'-trifluoromethylbiphenyl-2-yl)methyl]benzamide
  参考文献：
  名称：

  EP1180514

  摘要：

  公开号：
• 作为产物：
  描述：

  [4'-(三氟甲基)-2-联苯基]甲醇 在 三溴化磷 、 sodium hydroxide 、 水 作用下， 以 甲苯 、 四氢呋喃 为溶剂， 反应 0.17h， 生成 4'-trifluoromethyl-biphenyl-2-ylmethyl bromide
  参考文献：
  名称：

  WO2006/50035

  摘要：

  公开号：

文献信息

• Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor
  申请人：——

  公开号：US20010020110A1

  公开（公告）日：2001-09-06

  The present invention relates to a production method of compound [V] useful as an intermediate for medicaments and agrochemicals. The method includes reacting compound [III] with hexamethylenetetramine under heating to give compound [IV], and oxidizing the obtained compound [IV] with a halous acid salt or a ruthenium compound. According to the present invention, moreover, an organometallic compound having a tolyl group and compound [I] are cross-coupled in the presence of a catalyst to give compound [II] useful as an intermediate for medicaments and agrochemicals. The compound [II] is halogenated to give compound [III]. 1 wherein X is halogen atom.

  本发明涉及一种用作医药和农药中间体的化合物[V]的生产方法。该方法包括在加热下将化合物[III]与六甲基四胺反应以得到化合物[IV]，以及用卤素酸盐或钌化合物氧化所得到的化合物[IV]。根据本发明，另外，在催化剂存在下，将具有甲苯基的有机金属化合物与化合物[I]进行交叉偶联以得到用作医药和农药中间体的化合物[II]。化合物[II]被卤素化以得到化合物[III]。 1 其中X是卤素原子。
• Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents
  申请人：Shipps W. Gerald

  公开号：US20060111412A1

  公开（公告）日：2006-05-25

  The present invention provides compounds of formula I wherein X and R 1 -R 7 are as defined herein. Compositions containing these compounds, and methods for inhibiting HCV RNA-dependent RNA polymerase and treating hepatitis C and related disorders using these compounds and compositions are also provided.

  本发明提供了式I的化合物，其中X和R1-R7的定义如本文所述。还提供了包含这些化合物的组合物，以及使用这些化合物和组合物抑制HCV RNA依赖性RNA聚合酶和治疗丙型肝炎及相关疾病的方法。
• Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same
  申请人：——

  公开号：US20040224959A1

  公开（公告）日：2004-11-11

  Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R 1 and R 2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R 1 and R 2 , together with a nitrogen atom to which R 1 and R 2 are attached, may form a ring; R 3 and R 4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R 2 and R 3 may be attached to each other to form —(CH 2 ) m —, —N═CH—, —CH═N—, or —(C 1-6 alkyl)C═N—; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group —C(═O)N(R 5 )R 6 or group —C(═O)OR 7 , R 8 is absent or represents a bond, an oxygen atom, a sulfur atom, —SO 2 —, —SO—, —CH 2 —CH 2 —, or —CH═CH—, and R 9 and R 10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents —(CH 2 ) n —, —O—(CH 2 ) i —, or —C(═O)NH—(CH 2 ) i —. 1

  本发明涉及一种由公式（I）表示的化合物，其在肝脏中具有三酰甘油生物合成抑制活性和抑制含载脂蛋白B的脂蛋白从肝脏分泌的活性，特别是对含载脂蛋白B的脂蛋白的分泌具有出色的抑制活性，且不会出现在肝脏中积累脂质的副作用，对于治疗和预防高脂血症和动脉粥样硬化疾病非常有用。在公式（I）中，R1和R2代表烷基、烷氧基、环烷基、苯基、烯基、炔基或五元或六元饱和或不饱和杂环环，或R1和R2与R1和R2附着的氮原子一起形成环; R3和R4代表氢原子、烷基、卤素原子、羟基、腈、烷氧羰基、烷氧基或羧基; 或R2和R3可以相互附着以形成-（CH2）m-、-N═CH-、-CH═N-或-（C1-6烷基）C═N-; A、D、E和G每个代表一个碳原子，或任何一个A、D、E和G代表一个氮原子，其他三个代表一个碳原子; Q代表一个氮原子或一个碳原子; Y代表由公式（II）表示的基团，其中X代表氢原子、基团-C(═O)N(R5)R6或基团-C(═O)OR7，R8不存在或代表一个键，一个氧原子，一个硫原子，-SO2-，-SO-，-CH2-CH2-或-CH═CH-，R9和R10代表氢原子、烷基、烷氧基、卤素原子或羟基; Z代表-（CH2）n-、-O-（CH2）i-或-C(═O)NH-（CH2）i-。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1180514A1

  公开（公告）日：2002-02-20

  Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R1 and R2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R1 and R2, together with a nitrogen atom to which R1 and R2 are attached, may form a ring; R3 and R4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R2 and R3 may be attached to each other to form -(CH2)m-, -N=CH-, -CH=N-, or -(C1-6 alkyl)C=N-; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group -C(=O)N(R5)R6 or group -C(=O)OR7, R8 is absent or represents a bond, an oxygen atom, a sulfur atom, -SO2-, -SO-, -CH2-CH2-, or - CH=CH-, and R9 and R10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents - (CH2)n-, -O-(CH2)i-, or -C(=O)NH-(CH2)i-.

  本发明公开了式(I)代表的化合物，该化合物具有抑制肝脏中甘油三酯生物合成的活性和抑制肝脏分泌含脂蛋白B的脂蛋白的活性，特别是对肝脏分泌含脂蛋白B的脂蛋白具有极好的抑制活性，无肝脏中脂类蓄积的副作用，可用于治疗和预防高脂血症和动脉硬化性疾病。在式（I）中，R1 和 R2 代表烷基、烷氧基、环烷基、苯基、烯基、炔基或五元或六元饱和或不饱和杂环，或 R1 和 R2 与 R1 和 R2 所连接的氮原子一起可形成一个环；R3 和 R4 代表氢原子、烷基、卤素原子、羟基、腈基、烷氧羰基、烷氧基或羧基；或 R2 和 R3 可相互连接形成-(CH2)m-、-N=CH-、-CH=N-或-(C1-6 烷基)C=N-；A、D、E 和 G 各代表一个碳原子，或 A、D、E 和 G 中的任何一个代表一个氮原子，其他三个各代表一个碳原子； Q 代表一个氮原子或一个碳原子；Y 代表由式 (II) 所代表的基团，其中 X 代表氢原子、基团-C(=O)N(R5)R6 或基团-C(=O)OR7，R8 不存在或代表键、氧原子、硫原子、-SO2-、-SO-、-CH2-CH2- 或-CH=CH-，R9 和 R10 代表氢原子、烷基、烷氧基、卤素原子或羟基；Z 代表-(CH2)n-、-O-(CH2)-i 或-C(=O)NH-(CH2)-i。
• Inhibition of Nucleoside Transport by New Analogues of 4-Nitrobenzylthioinosine:  Replacement of the Ribose Moiety by Substituted Benzyl Groups
  作者：Reynier A. Tromp、Susan van Ameijde、Claudia Pütz、Corinna Sundermann、Bernd Sundermann、Jacobien K. von Frijtag Drabbe Künzel、Adriaan P. IJzerman

  DOI：10.1021/jm049735v

  日期：2004.10.1

  4-Nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. However, its highly polar nature is unfavorable for oral absorption and/or penetration into the CNS. In the search for compounds with lower polarity than NBTI we replaced its ribose moiety by substituted benzyl groups. Halogen, hydroxyl, (trifluoro)methyl(-oxy), nitro, and amine functionalities were among the substituents at the benzyl group. In general, substitution of the benzyl group resulted in a lower affinity for ENT1. Only 2-hydroxyl substitution showed a higher affinity. Most likely this is the result of hydrogen bonding. Substitution at the 2-position of the benzyl group with aryl groups was also addressed. Compared to parent compound carrying a 2-phenylbenzyl group, all synthesized analogues gave higher affinities. Introduction of fluoro, trifluoromethyl, methoxy, and hydroxyl groups at the phenyl group clearly showed that addition to the 4-position was preferable. Despite the highly different character of a ribose and a benzyl group, K-i values in the low nanomolar range were obtained for the benzyl-substituted derivatives. Compound 35, LUF5919, and compound 60, LUF5929, displayed the highest affinity (K-i = 39 nM for both compounds), having a polar surface area of 101 Angstrom(2) and 85 Angstrom(2), respectively.